BermanL, OnyemaI, BieberE. Letter: Mirtazapine-associated hyperkinetic movements in a 17-year-old with autism spectrum disorder and chronic catatonia: A case report. J Child Adolesc Psychopharmacol, 2025; 35(4):255–256; doi: 10.1089/cap.2024.0098
2.
BeserC, DavisG, O’ConnellM, et al.Letter: Agitation management in a 5-year-old boy with X chromosome-linked monoamine oxidase-A and monoamine oxidase-B deficiency. J Child Adolesc Psychopharmacol, 2025; 35(4):257–258; doi: 10.1089/cap.2024.0074
3.
DurakM, IşıkÜ. Letter: A rare case of dose-dependent priapism in a child with autism treated with aripiprazole and risperidone. J Child Adolesc Psychopharmacol, 2025; 35(4):259–260; doi: 10.1089/cap.2024.0134
4.
ElmaghrabyR, BlankE, MiyakoshiM, et al.Probing the neurodynamic mechanisms of cognitive flexibility in depressed individuals with autism spectrum disorder. J Child Adolesc Psychopharmacol, 2025; 35(4):231–243; doi: 10.1089/cap.2024.0109
5.
KevelsonSD. The curious case of therapist self-disclosure during pharmacotherapy in an autism center. J Child Adolesc Psychopharmacol, 2025; 35(4):175–177; doi: 10.1089/cap.2024.0149
6.
McKinneyWS, SchmittLM, De StefanoLA, et al.Results from a double-blind, randomized, placebo-controlled, single-dose, crossover trial of lovastatin or minocycline in fragile X syndrome. J Child Adolesc Psychopharmacol, 2025; 35(4):211–221; doi: 10.1089/cap.2024.0103
7.
SrinivasanA, LuccarelliJ, TamargoR, et al.Treat to sedation: Managing intravenous placement for electroconvulsive therapy in autism with intellectual disability and hyperactive catatonia. J Child Adolesc Psychopharmacol, 2025; 35(4):244–248; doi: 10.1089/cap.2025.0012
8.
ThomRP, WarrenTL, KhanS, et al.A blueprint for translational precision medicine in autism spectrum disorder and related neurogenetic syndromes. J Child Adolesc Psychopharmacol, 2025; 35(4):178–193; doi: 10.1089/cap.2025.0023
9.
ThomRP, RenziD, PecukonisM, et al.A prospective open-label trial of buspirone for the treatment of anxiety in Williams syndrome. J Child Adolesc Psychopharmacol, 2025; 35(4):222–230; doi: 10.1089/cap.2024.0124
10.
VerdesA, BhattachanS, KolevzonA, et al.Predictors of placebo response in the study of oxytocin in autism to improve reciprocal social behaviors. J Child Adolesc Psychopharmacol, 2025; 35(4):202–210; doi: 10.1089/cap.2024.0131
11.
WardC, ChildressA, MartinkoK, et al.Safety and efficacy of brexpiprazole in the treatment of irritability associated with autism spectrum disorder: An 8-week, phase 3, randomized, double-blind, placebo-controlled trial and 26-week open-label extension in children and adolescents. J Child Adolesc Psychopharmacol, 2025; 35(4):194–201; doi: 10.1089/cap.2024.0118
12.
WeasS, PawlowskiK, MillerM, et al.Psychotropic medication prescription patterns in Down syndrome in a large pediatric specialty clinic. J Child Adolesc Psychopharmacol, 2025; 35(4):249–254; doi: 10.1089/cap.2024.0028
